vs

Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Core Scientific, Inc. (CORZ). Click either name above to swap in a different company.

BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $79.8M, roughly 1.0× Core Scientific, Inc.). Core Scientific, Inc. runs the higher net margin — 268.5% vs 6.8%, a 261.6% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -16.0%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-450.8M).

BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.

Core Scientific is a leading digital asset and high-performance computing infrastructure provider. It operates large energy-efficient data centers across North America, offering cryptocurrency mining services, colocation hosting for blockchain and AI clients, and custom high-performance computing solutions for enterprise tech segments.

BLLN vs CORZ — Head-to-Head

Bigger by revenue
BLLN
BLLN
1.0× larger
BLLN
$83.5M
$79.8M
CORZ
Growing faster (revenue YoY)
BLLN
BLLN
+133.4% gap
BLLN
117.4%
-16.0%
CORZ
Higher net margin
CORZ
CORZ
261.6% more per $
CORZ
268.5%
6.8%
BLLN
More free cash flow
BLLN
BLLN
$457.2M more FCF
BLLN
$6.5M
$-450.8M
CORZ

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
BLLN
BLLN
CORZ
CORZ
Revenue
$83.5M
$79.8M
Net Profit
$5.7M
$214.2M
Gross Margin
69.9%
26.0%
Operating Margin
11.5%
-149.5%
Net Margin
6.8%
268.5%
Revenue YoY
117.4%
-16.0%
Net Profit YoY
138.3%
180.6%
EPS (diluted)
$0.10
$-1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLLN
BLLN
CORZ
CORZ
Q4 25
$79.8M
Q3 25
$83.5M
$81.1M
Q2 25
$78.6M
Q1 25
$79.5M
Q4 24
$94.9M
Q3 24
$38.4M
$95.4M
Q2 24
$141.1M
Q1 24
$179.3M
Net Profit
BLLN
BLLN
CORZ
CORZ
Q4 25
$214.2M
Q3 25
$5.7M
$-144.0M
Q2 25
$-936.8M
Q1 25
$576.3M
Q4 24
$-265.5M
Q3 24
$-14.9M
$-455.3M
Q2 24
$-902.2M
Q1 24
$210.7M
Gross Margin
BLLN
BLLN
CORZ
CORZ
Q4 25
26.0%
Q3 25
69.9%
4.8%
Q2 25
6.4%
Q1 25
10.3%
Q4 24
5.0%
Q3 24
52.6%
-0.2%
Q2 24
27.5%
Q1 24
43.3%
Operating Margin
BLLN
BLLN
CORZ
CORZ
Q4 25
-149.5%
Q3 25
11.5%
-67.6%
Q2 25
-33.4%
Q1 25
-59.1%
Q4 24
-41.9%
Q3 24
-32.9%
-43.2%
Q2 24
-64.3%
Q1 24
30.8%
Net Margin
BLLN
BLLN
CORZ
CORZ
Q4 25
268.5%
Q3 25
6.8%
-177.6%
Q2 25
-1191.4%
Q1 25
724.6%
Q4 24
-279.7%
Q3 24
-38.8%
-477.4%
Q2 24
-639.4%
Q1 24
117.5%
EPS (diluted)
BLLN
BLLN
CORZ
CORZ
Q4 25
$-1.63
Q3 25
$0.10
$-0.45
Q2 25
$-0.04
Q1 25
$1.24
Q4 24
$0.51
Q3 24
$-1.47
$-1.17
Q2 24
$-5.05
Q1 24
$0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLLN
BLLN
CORZ
CORZ
Cash + ST InvestmentsLiquidity on hand
$195.2M
$311.4M
Total DebtLower is stronger
$55.0M
Stockholders' EquityBook value
$-239.5M
$-962.7M
Total Assets
$327.5M
$2.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLLN
BLLN
CORZ
CORZ
Q4 25
$311.4M
Q3 25
$195.2M
$453.4M
Q2 25
$581.3M
Q1 25
$697.9M
Q4 24
$836.2M
Q3 24
$253.0M
Q2 24
$96.1M
Q1 24
$98.1M
Total Debt
BLLN
BLLN
CORZ
CORZ
Q4 25
Q3 25
$55.0M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BLLN
BLLN
CORZ
CORZ
Q4 25
$-962.7M
Q3 25
$-239.5M
$-1.3B
Q2 25
$-1.2B
Q1 25
$-308.8M
Q4 24
$-943.0M
Q3 24
$-242.9M
$-826.7M
Q2 24
$-1.2B
Q1 24
$-318.5M
Total Assets
BLLN
BLLN
CORZ
CORZ
Q4 25
$2.3B
Q3 25
$327.5M
$2.2B
Q2 25
$1.9B
Q1 25
$1.5B
Q4 24
$1.5B
Q3 24
$824.6M
Q2 24
$664.2M
Q1 24
$814.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLLN
BLLN
CORZ
CORZ
Operating Cash FlowLast quarter
$13.8M
$278.3M
Free Cash FlowOCF − Capex
$6.5M
$-450.8M
FCF MarginFCF / Revenue
7.7%
-565.1%
Capex IntensityCapex / Revenue
8.8%
914.0%
Cash ConversionOCF / Net Profit
2.42×
1.30×
TTM Free Cash FlowTrailing 4 quarters
$-779.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLLN
BLLN
CORZ
CORZ
Q4 25
$278.3M
Q3 25
$13.8M
$131.8M
Q2 25
$34.0M
Q1 25
$-45.0M
Q4 24
$42.9M
Q3 24
$5.7M
Q2 24
$1.2M
Q1 24
$22.2M
Free Cash Flow
BLLN
BLLN
CORZ
CORZ
Q4 25
$-450.8M
Q3 25
$6.5M
$-112.7M
Q2 25
$-87.3M
Q1 25
$-129.0M
Q4 24
$-52.1M
Q3 24
$-25.5M
Q2 24
$-1.9M
Q1 24
$-9.7M
FCF Margin
BLLN
BLLN
CORZ
CORZ
Q4 25
-565.1%
Q3 25
7.7%
-139.0%
Q2 25
-111.0%
Q1 25
-162.2%
Q4 24
-54.8%
Q3 24
-26.7%
Q2 24
-1.4%
Q1 24
-5.4%
Capex Intensity
BLLN
BLLN
CORZ
CORZ
Q4 25
914.0%
Q3 25
8.8%
301.5%
Q2 25
154.2%
Q1 25
105.6%
Q4 24
100.0%
Q3 24
32.7%
Q2 24
2.2%
Q1 24
17.8%
Cash Conversion
BLLN
BLLN
CORZ
CORZ
Q4 25
1.30×
Q3 25
2.42×
Q2 25
Q1 25
-0.08×
Q4 24
Q3 24
Q2 24
Q1 24
0.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLLN
BLLN

Prenatal$74.1M89%
Oncology$8.7M10%

CORZ
CORZ

Other$36.3M46%
Digital Asset Self Mining Service$31.8M40%
Colocation Service$11.6M15%

Related Comparisons